The multilevel regulation of CD95 signaling outcome

Experimental Oncology

Volumn 34, Issue 3, 2012, Pages 153-159

  Yurchenko, M ^a   Shlapatska, L M ^a   Sidorenko, S P ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Apoptosis; CD95; Death receptors; Signaling

Indexed keywords

CYTOCHROME C; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; EDELFOSINE; FAS ANTIGEN; MICRORNA; PROCASPASE 8; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL DIFFERENTIATION; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; ENDOCYTOSIS; ENZYME ACTIVITY; HUMAN; MITOCHONDRION; NONHUMAN; OLIGOMERIZATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANTIGENS, CD95; APOPTOSIS; CELL MEMBRANE; CELL SURVIVAL; HUMANS; MICRORNAS; MITOCHONDRIA; SIGNAL TRANSDUCTION;

EID: 84872438072     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009; 9: 501-7.
2. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57.
3. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-5. (Pubitemid 19196649)
4. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169: 1747-56. (Pubitemid 19126830)
5. Pinchouk VG, Sidorenko SP, Vetrova EP, et al. Monoclonal antibodies against the lymphoblastoid cell line RPMI-1788. Exp Oncol 1986; 8: 41-6 (in Russian).
6. Sidorenko SP, Berdova AG, Shlapatskaya LN, et al. Monoclonal antibodies IPO-4 recognizing the antigen of activated T and B human lymphocytes. Exp Oncol 1990; 12: 21-4 (in Russian).
7. Sidorenko SP, Vetrova EP, Yurchenko OV, et al. Monoclonal antibodies of IPO series against B cell differentiation antigens in leukemia and lymphoma immunophenotyping. Neoplasma 1992; 39: 3-9.
8. Robertson ML, Ritz J. Cluster report: CD95. In Schlossman SF, ed. Leucocyte Typing V. Oxford, New York, Tokyo: Oxford University Press, 1995: 1142-3.
9. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-43. (Pubitemid 121001362)
10. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501. (Pubitemid 32201945)
11. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J 2009; 23: 1625-37.
12. Cascino I, Fiucci G, Papoff G, et al . Three functional soluble forms of the human apoptosis-inducing Fas mo lecule are produced by alternative splicing. J Immunol 1995; 154: 2706-13.
13. Cascino I, Papoff G, Eramo A, et al . Soluble Fas/Apo-1 splicing variants and apoptosis. Front Biosci 1996; 1: d12-8.
14. Robertson MJ, Manley TJ, Pichert G, et al. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma 1995; 17: 51-61.
15. Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489-95.
16. Matsumura H, Shimizu Y, Ohsawa Y, et al. Necrotic death pathway in Fas receptor signaling. J Cell Biol 2000; 151: 1247-56.
17. Mapara MY, Bargou R, Zugck C, et al. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol 1993; 23: 702-8. (Pubitemid 23095107)
18. Siegel RM, Chan FK, Chun HJ, et al. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000; 1: 469-74.
19. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009; 30: 180-92.
20. Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med (Berl) 2000; 78: 312-25.
21. Tang D, Lotze MT, Kang R, et al. Apoptosis promotes early tumorigenesis. Oncogene 2011; 30: 1851-4.
22. Tauzin S, Debure L, Moreau JF, et al. CD95-mediated cell signaling in cancer: mutations and post-translational modulations. Cell Mol Life Sci 2012; 69: 1261-77.
23. Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415-29. (Pubitemid 23335841)
24. Barnhart BC, Pietras EM, Algeciras-Schimnich A, et al. CD95 apoptosis resistance in certain cells can be overcome by noncanonical activation of caspase-8. Cell Death Differ 2005; 12: 25-37. (Pubitemid 40090026)
25. Cascino I, Papoff G, De Maria R, et al. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 1996; 156: 13-7. (Pubitemid 26006942)
26. Boldin MP, Mett IL, Varfolomeev EE, et al . Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem 1995; 270: 387-91.
27. Chan FK, Chun HJ, Zheng L, et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288: 2351-4. (Pubitemid 30448156)
28. Siegel RM, Frederiksen JK, Zacharias DA, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000; 288: 2354-7. (Pubitemid 30448157)
29. Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-78. (Pubitemid 24006113)
30. Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205-13. (Pubitemid 28189110)
31. O'Reilly LA, Tai L, Lee L, et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009; 461: 659-63.
32. Lavrik IN, Golks A, Riess D, et al. Analysis of CD95 threshold signaling: triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J Biol Chem 2007; 282: 13664-71. (Pubitemid 47100557)
33. Peter ME, Legembre P, Barnhart BC. Does CD95 have tumor promoting activities? Biochim Biophys Acta 2005; 1755: 25-36.
34. Lee KH, Feig C, Tchikov V, et al. The role of receptor internalization in CD95 signaling. EMBO J 2006; 25: 1009-23. (Pubitemid 43372115)
35. Siegel RM, Muppidi JR, Sarker M, et al. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol 2004; 167: 735-44. (Pubitemid 39565153)
36. Feig C, Tchikov V, Schutze S, et al. Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J 2007; 26: 221-31. (Pubitemid 46094713)
37. Chakrabandhu K, Herincs Z, Huault S, et al. Palmitoylation is required for efficient Fas cell death signaling. EMBO J 2007; 26: 209-20. (Pubitemid 46094712)
38. Chakrabandhu K, Huault S, Garmy N, et al. The extracellular glycosphingolipid-binding motif of Fas defines its internalization route, mode and outcome of signals upon activation by ligand. Cell Death Differ 2008; 15: 1824-37.
39. Gajate C, Mollinedo F. Lipid rafts and Fas/CD95 signaling in cancer chemotherapy. Recent Pat Anticancer Drug Discov 2011; 6: 274-83.
40. Scott FL, Stec B, Pop C, et al. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 2009; 457: 1019-22.
41. Tibbetts MD, Zheng L, Lenardo MJ. The death effector domain protein family: regulators of cellular homeostasis. Nat Immunol 2003; 4: 404-9. (Pubitemid 36592429)
42. Eberstadt M, Huang B, Chen Z, et al. NMR structure and mutagenesis of the FADD (Mort1) death-effector domain. Nature 1998; 392: 941-5. (Pubitemid 28232068)
43. Krueger A, Baumann S, Krammer PH, et al. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001; 21: 8247-54. (Pubitemid 33108586)
44. Lavrik IN, Krammer PH. Regulation of CD95/Fas signaling at the DISC. Cell Death Differ 2012; 19: 36-41.
45. Fricker N, Beaudouin J, Richter P, et al. Model-based dissection of CD95 signaling dynamics reveals both a pro- and antiapoptotic role of c-FLIPL. J Cell Biol 2010; 190: 377-89.
46. Kober AM, Legewie S, Pforr C, et al. Caspase-8 activity has an essential role in CD95/Fas-mediated MAPK activation. Cell Death Dis 2011; 2: e212.
47. Lavrik IN, Mock T, Golks A, et al. CD95 stimulation results in the formation of a novel death effector domain protein-containing complex. J Biol Chem 2008; 283: 26401-8.
48. Hughes MA, Harper N, Butterworth M, et al. Reconstitution of the death-inducing signaling complex reveals a substrate switch that determines CD95-mediated death or survival. Mol Cell 2009; 35: 265-79.
49. Kang TB, Oh GS, Scandella E, et al. Mutation of a self-processing site in caspase-8 compromises its apoptotic but not its nonapoptotic functions in bacterial artificial chromosome-transgenic mice. J Immunol 2008; 181: 2522-32.
50. Cursi S, Rufini A, Stagni V, et al. Src kinase phosphorylates caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J 2006; 25: 1895-905.
51. Matthess Y, Raab M, Sanhaji M, et al. Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating cas pase-8 activity. Mol Cell Biol 2010; 30: 5726-40.
52. Jin Z, Li Y, Pitti R, et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009; 137: 721-35.
53. Scaffidi C, Schmitz I, Zha J, et al. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 1999; 274: 22532-8.
54. Korsmeyer SJ, Wei MC, Saito M, et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7: 1166-73. (Pubitemid 32042223)
55. Eramo A, Sargiacomo M, Ricci-Vitiani L, et al . CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur J Immunol 2004; 34: 1930-40. (Pubitemid 39256074)
56. Festjens N, Vanden Berghe T, Cornelis S, et al. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007; 14: 400-10.
57. Meylan E, Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci 2005; 30: 151-9. (Pubitemid 40332531)
58. Kamarajan P, Bunek J, Lin Y, et al. Receptor-interacting protein shuttles between cell death and survival signaling pathways. Mol Biol Cell 2010; 21: 481-8.
59. Legembre P, Barnhart BC, Zheng L, et al. Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds. EMBO Rep 2004; 5: 1084-9. (Pubitemid 39600208)
60. Kinnally KW, Antonsson B. A tale of two mitochondrial channels, MAC and PTP, in apoptosis. Apoptosis 2007; 12: 857-68. (Pubitemid 46653291)
61. Dejean LM, Martinez-Caballero S, Manon S, et al. Regulation of the mitochondrial apoptosis-induced channel, MAC, by BCL-2 family proteins. Biochim Biophys Acta 2006; 1762: 191-201.
62. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-10. (Pubitemid 34685698)
63. de Almagro MC, Vucic D. The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol 2012; 34: 200-11.
64. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012; 11: 109-24.
65. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12: 1543-68. (Pubitemid 47106887)
66. Park SM, Peter ME. microRNAs and death receptors. Cytokine Growth Factor Rev 2008; 19: 303-11.
67. Garofalo M, Condorelli GL, Croce CM, et al. MicroRNAs as regulators of death receptors signaling. Cell Death Differ 2010; 17: 200-8.
68. Patron JP, Fendler A, Bild M, et al. MiR-133b targets antiapoptotic genes and enhances death receptor-induced apoptosis. PLoS One 2012; 7: e35345.
69. Hemond M, Rothstein TL, Wagner G. Fas apoptosis inhibitory molecule contains a novel beta-sandwich in contact with a partially ordered domain. J Mol Biol 2009; 386: 1024-37.
70. Rothstein TL. Inducible resistance to Fas-mediated apoptosis in B cells. Cell Res 2000; 10: 245-66.
71. Segura MF, Sole C, Pascual M, et al. The long form of Fas apoptotic inhibitory molecule is expressed specifically in neurons and protects them against death receptor-triggered apoptosis. J Neurosci 2007; 27: 11228-41. (Pubitemid 47628520)